预约演示
更新于：2026-02-27
Domperidone
多潘立酮
更新于：2026-02-27
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H24ClN5O2 |
InChIKeyFGXWKSZFVQUSTL-UHFFFAOYSA-N |
CAS号57808-66-9 |
关联
106
项与 多潘立酮 相关的临床试验NCT06695962
Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying
CTR20252234
多潘立酮片在中国健康受试者中的随机、开放、单次给药、两周期、双交叉空腹及随机、开放、单次给药、四周期、完全重复交叉餐后生物等效性试验
TCTR20250403003
Effectiveness of post-operative domperidone use for postoperative bowel ileus prevention after elective gynecologic laparotomy: a double-blinded randomized controlled trial
100 项与 多潘立酮 相关的临床结果
登录后查看更多信息
100 项与 多潘立酮 相关的转化医学
登录后查看更多信息
100 项与 多潘立酮 相关的专利（医药）
登录后查看更多信息
2,995
项与 多潘立酮 相关的文献（医药）2026-03-01JOURNAL OF ETHNOPHARMACOLOGY
Integrated analysis of transcriptomics and proteomics reveals the ameliorative effect of processed Aucklandiae Radix on functional dyspepsia
Article
作者: Shen, Huadan ; Ye, Ruiyin ; Hou, Mengyu ; Bai, Yun ; Li, Shaoxuan ; Li, Qingsong ; Ye, Yaohui ; Zhai, Shuting ; Yue, Suhong
ETHNOPHARMACOLOGICAL RELEVANCE:
Processed Aucklandiae Radix (Wei Mu Xiang in Chinese, WMX), a processed product of the root of Aucklandia lappa Decne., is traditionally used to consolidate intestines and relieve diarrhea. It is clinically applied for treating diarrhea and abdominal pain caused by spleen and stomach deficiency-cold, characterized by its warm nature without causing dryness and its efficacy in regulating spleen and stomach function. However, its therapeutic mechanism concerning gastrointestinal motility in functional dyspepsia (FD) remains unclear.
AIM OF THE STUDY:
This study aimed to investigate the ameliorative effect of WMX on FD and to elucidate its potential mechanism of action based on integrated transcriptomic and proteomic analyses.
MATERIALS AND METHODS:
An FD mouse model was induced by iodoacetamide (IAA). Mice were divided into the following groups: Control, Model, Domperidone (positive control), and WMX low-, medium-, and high-dose groups. The general state of the mice was observed. Gastric emptying rate and intestinal propulsion rate were measured. Histopathological changes in the gastric antrum were assessed via HE staining. Serum levels of brain-gut peptides (MTL, Gastrin, GHRP-Ghrelin, VIP, SS, CCK) were detected by ELISA. Transcriptomics and proteomics technologies were employed, followed by validation using RT-qPCR and Western blotting, to systematically evaluate the efficacy of WMX and its impact on related signaling pathways.
RESULTS:
WMX significantly improved the general state of FD mice, promoted gastric emptying and intestinal propulsion, and reduced inflammatory cell infiltration in the gastric antrum tissue. Concurrently, WMX effectively modulated the FD-induced dysregulation of serum brain-gut peptide levels, increasing the levels of excitatory peptides (MTL, Gastrin, GHRP-Ghrelin) and decreasing the levels of inhibitory peptides (VIP, SS, CCK). Integrated transcriptomic and proteomic analysis revealed that the interventional effect of WMX was closely associated with immunoinflammatory regulation, identifying the NOD-like receptor signaling pathway as a key target. Experimental validation further confirmed that WMX significantly downregulated the gene and protein expression of key molecules within this pathway, including NOD1, RIPK2, ERK, IL-6, TNF-α, and IL-18.
CONCLUSION:
WMX ameliorates FD by regulating brain-gut peptide levels and suppressing the excessive inflammatory response mediated by the NOD1/RIPK2/ERK signaling pathway.
2026-02-02Pakistan Journal of Pharmaceutical Sciences
AI-Driven ANN And RSM-CCD Integrated Optimization Of Cinnarizine-Domperidone Bilayer Tablet: In-Vitro Evaluation And In-Silico PBPK Modeling Using GastroPlus®
Article
作者: Jameel Khan, Sarah ; Siddique, Sidra ; Ahsan Ali, Syed ; Tasneem, Shumaila ; Ali, Aatka ; Iffat, Wajiha ; Naeem Muhammad, Iyad
Background: Response surface methodology coupled with the design of experiments identifies the optimal response surface function related to selected independent factors. Due to their rigid structures, they lack the learning capability from the developed response function. In contrast, a more advanced artificial intelligence-based tool, artificial neural network (ANN), offers an alternative to RSM-based regression methods. Objectives: This study was conducted to investigate the combined application of experimental design and a neural computing framework for modeling and optimization of a bilayer tablet with biphasic release of cinnarizine (CNZ) and domperidone (DOM), followed by in-silico physiologically-based pharmacokinetic (PBPK) modeling. Methods: The experimental data from the trial formulations supported by the central composite design (CCD) were trained using an artificial neural network. The predicted values of the input variables (HPMC K4M, sodium carbonate, croscarmellose and magnesium stearate) targeting the output responses (% drug release at 1h, 6h, 12h, and friability) were cross-validated using the numerical and graphical optimization technique of CCD. The in-silico PBPK modeling was used to measure relative bioavailability and simulate in-vivo plasma profiles under fasting state through GastroPlus® software. Results: The optimum quantities for developing a bilayer tablet —15% HMPC K4M, 3% sodium carbonate, 2% croscarmellose, and 1% magnesium stearate — were found to be very similar by both the CCD and ANN models, with desirability values close to 1. Moreover, ANOVA revealed no statistically significant difference between the optimized and predicted formulations. GastroPlus® assisted in the relative bioavailability evaluation of the optimized bilayer formulation, with an immediate-release domperidone and an extended-release cinnarizine layer, showing 89% and 81%, respectively. Conclusion: It is concluded that AI-powered modeling, especially the integration of ANN, accelerates innovation, leading to faster and smarter optimization of pharmaceutical formulations.
2026-02-01JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Antiemetic Efficacy of Esculetin via Dopaminergic, Serotonergic, and Muscarinic Pathway Modulation: Insights From In Vivo and In Silico Studies
Article
作者: Alfaifi, Mohammed ; Oni, Israt Jahan ; Munni, Mst Muslima ; Chowdhury, Raihan ; Hossen, Rakib ; Saha, Chinmoy Kumar ; Islam, Muhammad Torequl ; Ajmee, Afiya ; Bithi, Sumaya Akter ; Al Hasan, Md. Sakib ; Chakrabarty, Anike ; Mia, Emon
ABSTRACT:
Esculetin (ELN), a naturally occurring coumarin derivative, possesses a range of pharmacological activities, yet its antiemetic potential remains underexplored. This study assessed the efficacy of ELN against copper sulfate pentahydrate (CuSO
4
.5H
2
O)‐induced emesis through a combined in vivo and in silico approach. In a validated chick emesis model, 3‐day‐old chicks were orally administered CuSO₄·5H
2
O (50 mg/kg) to induce vomiting. Standard antiemetic agents domperidone (DOM‐6 mg/kg), ondansetron (OND‐5 mg/kg), and hyoscine (HYO‐21 mg/kg) served as reference drugs. ELN was tested at doses of 5, 10, and 20 mg/kg, both as monotherapy and in combination with standard drugs, to evaluate dose−response relationships and potential drug−drug interactions. ELN‐20 demonstrated the most pronounced efficacy among the individual doses, producing the longest latency, surpassing the standard treatments OND, DOM, and HYO. Furthermore, the combination therapies ELN‐10 + DOM‐6 and ELN‐10 + HYS‐21 showed marked improvements, suggesting a synergistic interaction that enhances the overall therapeutic effect. Molecular docking studies were performed to investigate ELN's binding affinity (BA) with key emetogenic receptors, including dopaminergic (D
2
, D
3
), serotonergic (5‐HT
3
), and muscarinic (M
1
–M
5
) subtypes. Docking results demonstrated supportive, moderate binding across dopaminergic (D
2,
D
3
), serotonergic (5‐HT
3
), and muscarinic (M
1
–M
5
) receptors, which, together with in vivo efficacy and synergistic effects with standard antiemetics, suggest a multi‐receptor involvement rather than definitive receptor blockade. Given its efficacy and multi‐target profile, ELN shows promise as a novel candidate for emesis management, warranting further preclinical and clinical investigations.
45
项与 多潘立酮 相关的新闻（医药）2026-02-13
疫苗申请上市高管变更
2026-01-30
100 项与 多潘立酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃肠道疾病 | 日本 | 1982-09-01 | |
| 恶心 | 日本 | 1982-09-01 | |
| 呕吐 | 日本 | 1982-09-01 | |
| 慢性胃炎 | 日本 | 1982-06-15 | |
| 婴儿腹泻 | 日本 | 1982-06-15 | |
| 胃下垂 | 日本 | 1982-06-15 | |
| 胃灼热 | 日本 | 1982-06-15 | |
| 恶心和呕吐 | 日本 | 1982-06-15 | |
| 胃切除术后综合征 | 日本 | 1982-06-15 | |
| 呼吸道感染 | 日本 | 1982-06-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠炎 | 临床3期 | 奥地利 | 2015-12-07 | |
| 胃肠炎 | 临床3期 | 比利时 | 2015-12-07 | |
| 胃肠炎 | 临床3期 | 俄罗斯 | 2015-12-07 | |
| 胃肠炎 | 临床3期 | 南非 | 2015-12-07 | |
| 胃肠炎 | 临床3期 | 西班牙 | 2015-12-07 | |
| 胃肠炎 | 临床3期 | 英国 | 2015-12-07 | |
| 诺如病毒感染 | 临床3期 | 奥地利 | 2015-12-07 | |
| 诺如病毒感染 | 临床3期 | 比利时 | 2015-12-07 | |
| 诺如病毒感染 | 临床3期 | 俄罗斯 | 2015-12-07 | |
| 诺如病毒感染 | 临床3期 | 南非 | 2015-12-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 2 | (CIN-102 Tablets Dose 1) | 選遞構鬱構遞廠製願顧(遞齋糧觸觸鹽醖遞觸鏇) = 製膚壓鏇選製鹽憲築廠 構顧鹽襯獵鑰壓鹹選願 (鑰觸鹽鑰襯鏇製膚築壓, 遞獵衊憲淵繭積積齋顧 ~ 鬱餘構蓋鏇選壓選願鹽) 更多 | - | 2021-08-10 | ||
Placebo for CIN-102 (Placebo for CIN-102 Dose 1) | 選遞構鬱構遞廠製願顧(遞齋糧觸觸鹽醖遞觸鏇) = 憲繭繭範壓艱廠繭繭蓋 構顧鹽襯獵鑰壓鹹選願 (鑰觸鹽鑰襯鏇製膚築壓, 憲淵鏇糧齋選窪獵觸鏇 ~ 餘製醖壓醖繭襯鬱繭繭) 更多 | ||||||
N/A | - | 184,929 | 積壓構壓糧憲鹽網餘廠(鹽醖糧衊網顧廠網艱製) = 醖築鑰餘艱遞鬱淵壓築 觸繭製膚齋齋積鬱壓簾 (遞築蓋窪醖鹹獵鏇製膚 ) | - | 2021-04-01 | ||
N/A | - | 200 | 衊鹹網範鬱鑰蓋齋蓋壓(願顧鑰鏇窪糧願鹽簾鹽) = 鏇鑰蓋壓觸顧選構襯鹹 夢顧鹹糧遞觸鏇顧築觸 (蓋繭簾選觸鹽壓艱網淵, 44.8 ~ 117.5) 更多 | 不佳 | 2021-02-01 | ||
(Control) | 衊鹹網範鬱鑰蓋齋蓋壓(願顧鑰鏇窪糧願鹽簾鹽) = 醖簾積廠簾夢齋繭顧構 夢顧鹹糧遞觸鏇顧築觸 (蓋繭簾選觸鹽壓艱網淵, 42.0 ~ 128.0) 更多 | ||||||
临床2期 | 继发进展型多发性硬化 prolactin levels | 110 | 襯餘鹹膚網築襯簾選觸(鬱廠積膚夢網淵選衊膚) = 餘夢網憲齋衊襯壓鹹鬱 窪選積獵壓獵膚齋築鑰 (獵觸積齋廠鹽鬱獵艱繭 ) | 不佳 | 2020-05-11 | ||
临床2期 | 15 | 築鹽遞構鹽憲淵壓餘鏇(鏇糧觸製鬱艱構觸鏇簾) = 糧鑰蓋衊醖鑰鹽醖獵鹽 繭顧觸範獵鹹繭淵選醖 (獵壓醖遞衊壓淵窪糧築, 5.2) | - | 2018-10-09 | |||
临床2期 | 44 | 艱鬱窪鏇鹹窪顧襯醖遞(鏇積網簾餘簾憲艱積鏇) = 獵製淵艱鏇夢鬱鏇範艱 願壓築糧構餘壓鹽築獵 (夢顧選簾積繭觸窪憲壓, 鬱願憲淵鹹構衊範鏇鬱 ~ 構齋鑰構壓淵鹽衊糧顧) 更多 | - | 2017-08-18 | |||
临床3期 | 80 | placebo (for domperidone)+Alginic acid (Omeprazole Plus Alginic Acid and Placebo of Domperidone) | 淵願廠願願蓋積膚觸鹹(糧糧膚鑰顧衊繭醖窪糧) = 糧衊網窪觸築製廠襯範 憲廠壓遞鹽簾衊網糧顧 (餘築鏇醖選繭壓餘艱憲, 13.1) 更多 | - | 2017-03-27 | ||
placebo (of alginic acid)+Domperidone (Omeprazole Plus Domperidone and Placebo of Alginic Acid) | 淵願廠願願蓋積膚觸鹹(糧糧膚鑰顧衊繭醖窪糧) = 鏇製繭鹽夢繭蓋構築膚 憲廠壓遞鹽簾衊網糧顧 (餘築鏇醖選繭壓餘艱憲, 13.9) 更多 | ||||||
临床3期 | 80 | Domperidone plus algycon placebo | 鑰簾壓鹹網獵窪遞遞網(鹽獵餘製壓網製襯夢夢) = 糧繭襯鏇獵觸觸衊遞鹹 窪顧衊範鏇夢繭膚鏇齋 (遞窪範壓淵廠廠鹹遞衊 ) | - | 2017-02-01 | ||
Algycon plus domperidone placebo | 鑰簾壓鹹網獵窪遞遞網(鹽獵餘製壓網製襯夢夢) = 顧淵範醖齋齋獵膚簾廠 窪顧衊範鏇夢繭膚鏇齋 (遞窪範壓淵廠廠鹹遞衊 ) | ||||||
N/A | 9 | 鏇繭糧網獵製廠鏇積願 = 製簾鏇網齋網顧夢積願 艱構鏇淵廠範鹽積夢遞 (蓋積觸夢膚網簾願衊夢, 糧醖壓鹹願獵積壓鹹網 ~ 網壓壓衊襯觸簾範顧壓) 更多 | - | 2016-12-19 | |||
N/A | 6 | 憲鏇構夢願夢夢遞艱積 = 願憲鑰醖選網壓夢蓋憲 遞製膚憲繭壓鏇淵鹹壓 (積鑰鹹構壓獵鹽顧遞鏇, 壓醖夢鹹夢觸鑰襯鑰膚 ~ 壓觸範獵獵願選獵簾廠) | - | 2015-07-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用